International Clinical Trial: A First-in-human Trial of SZN-8141 in Diabetic Macular Edema

Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07817121) titled 'A First-in-human Trial of SZN-8141 in Diabetic Macular Edema' on Sept. 8.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor).

Primary Sponsor: Surrozen Operating, Inc.

Condition: Diabetic Macular Edema (DME)

Intervention: Biological: SZN-8141 for Injection

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: October 30, 2026

Target Sample Size: 9

To know more, visit https://clinicaltrials.gov/study/NCT07817121

Published by HT Digital Content Services with...